TRACON Pharmaceuticals, Inc.

218 articles about TRACON Pharmaceuticals, Inc.

• TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/11/2021

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the second quarter ended June 30, 2021.

• TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial- Trial to Continue as Planned

  8/9/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), today announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of 12 week safety data from more than 20 patients enrolled into the trial as of May 2021.

• TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference - Aug 03, 2021

  8/3/2021

  TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 10, 2021 at 12:00pm Eastern Time.

• TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021

  7/28/2021

  TRACON Pharmaceuticals (NASDAQ:TCON), announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021.

• TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

  7/22/2021

  TRACON Pharmaceuticals announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,926,702 shares of common stock of the Company at a price to the public of $3.82 per share, less underwriting discounts and commissions.

• TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

  7/21/2021

  TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Company’s common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions.

• TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

  7/20/2021

  TRACON Pharmaceuticals announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi.

• TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award

  6/30/2021

  TRACON Pharmaceuticals announced today the appointment of Ya Huang as Executive Director of Statistical Programming and the grant of an inducement equity award to Mr. Huang.

• TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

  6/29/2021

  TRACON Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to envafolimab

• TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

  6/4/2021

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Company’s Phase 1 study of TJ004309 and Tecentriq® (atezolizumab) at the American Society of Clinical Oncology (ASCO) virtual annual meeting.

• TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialTrial to Continue as Planned

  6/1/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S.,

• TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 2:30pm Eastern Time.

• TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

  5/20/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology

• TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/5/2021

  TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced financial results for the first quarter ended March 31, 2021.

• TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics

  5/3/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Dongliang Zhuang, Ph.D.

• TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021

  4/28/2021

  TRACON Pharmaceuticals announced that it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, May 5, 2021.

• TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual MeetingPoster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma

  3/23/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that a poster highlighting the pivotal Phase 2 ENVASARC

• TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/9/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), oday announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 at 3:10pm Eastern Time.

• TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

  3/8/2021

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President,

• TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer